Shionogi & Co.,Ltd. (SHWDY) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

499.68B

Net Income (TTM)

205.16B

Op. CF (TTM)

213.57B

Latest newsMore news →

StemRim announced results of clinical trials for 'Redasemtide' in epidermolysis bullosa and acute ischemic stroke patients, with the stroke trial failing to meet its primary endpoint.11d ago

Shionogi plans to start a clinical trial in 2027 for its RS virus treatment drug targeting infants under two years old.18d ago

Latest newsMore news →

StemRim announced results of clinical trials for 'Redasemtide' in epidermolysis bullosa and acute ischemic stroke patients, with the stroke trial failing to meet its primary endpoint.11d ago Shionogi plans to start a clinical trial in 2027 for its RS virus treatment drug targeting infants under two years old.18d ago